{"entity":{"id":"carlos-caldas","kind":"person","name":"Carlos Caldas","aka":[],"tldr":"Led METABRIC, which used 2,000 tumours to define ten genomic subtypes of breast cancer and their long-term outcomes.","summary":"Carlos Caldas led METABRIC, the integrated genomic and transcriptomic analysis of 2,000 breast cancers that defined ten integrative clusters with distinct 20-year outcomes, and the follow-up showing that late relapse risk differs sharply between them. His group built a large breast cancer PDX biobank for functional testing and studies the evolution of metastatic breast cancer. He led the Cambridge Breast Cancer Research Unit.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Carlos_Caldas","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caldas%20C%5BAuthor%5D%20breast%20genomic%20METABRIC"}],"tags":["genomics","breast","classification"],"related":[],"cancers":["breast-hr-positive","tnbc","breast-her2-positive"],"sections":[],"technologies":["wes-wgs","rna-seq","pdx-models"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Medicine, University of Cambridge; Senior Group Leader, CRUK Cambridge Institute","institutionId":"cruk-cambridge-centre","specialisms":["Breast cancer genomics","Integrative clusters","Patient-derived xenografts","Functional genomics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Caldas%20C%5BAuthor%5D%20breast%20genomic%20METABRIC"}],"papers":[{"title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups (METABRIC)","journal":"Nature","year":2012,"doi":"10.1038/nature10983"},{"title":"Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups","journal":"Nature","year":2019,"doi":"10.1038/s41586-019-1007-8"}],"orcid":"0000-0003-3547-1489"},"route":"/people/carlos-caldas/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"institution":[{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/"}]}}